

## Hyperthermia Treatment for Cancer

Last Review Date: January 14, 2022

Number: MG.MM.RA.15C4

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Guideline

Hyperthermia and concurrent radiation therapy treatment is considered medically necessary for **any**:

- A. Superficially recurrent melanoma
- B. Chest wall recurrence of breast cancer
- C. Recurrent cervical lymph nodes from head and neck cancer

Treatment of the above conditions will be approved in the absence of **both**:

- A. Metastatic disease for which chemotherapy or hormonal therapy is being given concurrently or planned
- B. Evidence of tumor recurrence exceeding 4 cm in depth

### Utilization

No more than 10 hyperthermia treatments delivered twice weekly at 72-hour intervals should be utilized.

### Limitations/Exclusions

The use of intraluminal, endocavitary, interstitial, regional deep tissue hyperthermia exceeding 4 cm in depth, and whole body hyperthermia is considered experimental, investigational, or unproven (EIU).

## Applicable Procedure Codes

|       |  |
|-------|--|
| 77600 | Hyperthermia, externally generated; superficial (ie, heating to a depth of 4 cm or less) |
|-------|--|

## Applicable Diagnosis Codes

|         |  |
|---------|--|
| C43.0   | Malignant melanoma of lip  |
| C43.10  | Malignant melanoma of unspecified eyelid, including canthus        |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus        |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus        |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus         |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus         |
| C43.20  | Malignant melanoma of unspecified ear and external auricular canal |
| C43.21  | Malignant melanoma of right ear and external auricular canal       |
| C43.22  | Malignant melanoma of left ear and external auricular canal        |
| C43.30  | Malignant melanoma of unspecified part of face                     |
| C43.31  | Malignant melanoma of nose   |
| C43.39  | Malignant melanoma of other parts of face                          |
| C43.4   | Malignant melanoma of scalp and neck                               |
| C43.51  | Malignant melanoma of anal skin                                    |
| C43.52  | Malignant melanoma of skin of breast                               |
| C43.59  | Malignant melanoma of other part of trunk                          |
| C43.60  | Malignant melanoma of unspecified upper limb, including shoulder   |
| C43.61  | Malignant melanoma of right upper limb, including shoulder         |
| C43.62  | Malignant melanoma of left upper limb, including shoulder          |
| C43.70  | Malignant melanoma of unspecified lower limb, including hip        |
| C43.71  | Malignant melanoma of right lower limb, including hip              |
| C43.72  | Malignant melanoma of left lower limb, including hip               |
| C43.8   | Malignant melanoma of overlapping sites of skin                    |
| C43.9   | Malignant melanoma of skin, unspecified                            |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast       |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast        |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast         |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast          |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast   |
| C50.111 | Malignant neoplasm of central portion of right female breast       |
| C50.112 | Malignant neoplasm of central portion of left female breast        |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast         |
| C50.122 | Malignant neoplasm of central portion of left male breast          |
| C50.129 | Malignant neoplasm of central portion of unspecified male breast   |
| C50.211 | Malignant neoplasm of upper-inner quadrant of right female breast  |
| C50.212 | Malignant neoplasm of upper-inner quadrant of left female breast   |

|         |  |
|---------|--|
| C50.219 | Malignant neoplasm of upper-inner quadrant of unspecified female breast            |
| C50.221 | Malignant neoplasm of upper-inner quadrant of right male breast                    |
| C50.222 | Malignant neoplasm of upper-inner quadrant of left male breast                     |
| C50.229 | Malignant neoplasm of upper-inner quadrant of unspecified male breast              |
| C50.311 | Malignant neoplasm of lower-inner quadrant of right female breast                  |
| C50.312 | Malignant neoplasm of lower-inner quadrant of left female breast                   |
| C50.319 | Malignant neoplasm of lower-inner quadrant of unspecified female breast            |
| C50.321 | Malignant neoplasm of lower-inner quadrant of right male breast                    |
| C50.322 | Malignant neoplasm of lower-inner quadrant of left male breast                     |
| C50.329 | Malignant neoplasm of lower-inner quadrant of unspecified male breast              |
| C50.411 | Malignant neoplasm of upper-outer quadrant of right female breast                  |
| C50.412 | Malignant neoplasm of upper-outer quadrant of left female breast                   |
| C50.419 | Malignant neoplasm of upper-outer quadrant of unspecified female breast            |
| C50.421 | Malignant neoplasm of upper-outer quadrant of right male breast                    |
| C50.422 | Malignant neoplasm of upper-outer quadrant of left male breast                     |
| C50.429 | Malignant neoplasm of upper-outer quadrant of unspecified male breast              |
| C50.511 | Malignant neoplasm of lower-outer quadrant of right female breast                  |
| C50.512 | Malignant neoplasm of lower-outer quadrant of left female breast                   |
| C50.519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast            |
| C50.521 | Malignant neoplasm of lower-outer quadrant of right male breast                    |
| C50.522 | Malignant neoplasm of lower-outer quadrant of left male breast                     |
| C50.529 | Malignant neoplasm of lower-outer quadrant of unspecified male breast              |
| C50.611 | Malignant neoplasm of axillary tail of right female breast                         |
| C50.612 | Malignant neoplasm of axillary tail of left female breast                          |
| C50.619 | Malignant neoplasm of axillary tail of unspecified female breast                   |
| C50.621 | Malignant neoplasm of axillary tail of right male breast                           |
| C50.622 | Malignant neoplasm of axillary tail of left male breast                            |
| C50.629 | Malignant neoplasm of axillary tail of unspecified male breast                     |
| C50.811 | Malignant neoplasm of overlapping sites of right female breast                     |
| C50.812 | Malignant neoplasm of overlapping sites of left female breast                      |
| C50.819 | Malignant neoplasm of overlapping sites of right female breast                     |
| C50.821 | Malignant neoplasm of overlapping sites of right male breast                       |
| C50.822 | Malignant neoplasm of overlapping sites of left male breast                        |
| C50.829 | Malignant neoplasm of overlapping sites of unspecified male breast                 |
| C50.911 | Malignant neoplasm of unspecified site of right female breast                      |
| C50.912 | Malignant neoplasm of unspecified site of right female breast                      |
| C50.919 | Malignant neoplasm of unspecified site of unspecified female breast                |
| C50.921 | Malignant neoplasm of unspecified site of right male breast                        |
| C50.922 | Malignant neoplasm of unspecified site of left male breast                         |
| C50.929 | Malignant neoplasm of unspecified site of unspecified male breast                  |
| C76.0   | Malignant neoplasm of head, face and neck  |
| C77.0   | Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck |
| C79.81  | Secondary malignant neoplasm of breast   |

|         |  |
|---------|--|
| D03.0   | Melanoma in situ of lip  |
| D03.10  | Melanoma in situ of unspecified eyelid, including canthus        |
| D03.111 | Melanoma in situ of right upper eyelid, including canthus        |
| D03.112 | Melanoma in situ of right lower eyelid, including canthus        |
| D03.121 | Melanoma in situ of left upper eyelid, including canthus         |
| D03.122 | Melanoma in situ of left lower eyelid, including canthus         |
| D03.20  | Melanoma in situ of unspecified ear and external auricular canal |
| D03.21  | Melanoma in situ of right ear and external auricular canal       |
| D03.22  | Melanoma in situ of left ear and external auricular canal        |
| D03.30  | Melanoma in situ of unspecified part of face                     |
| D03.39  | Melanoma in situ of other parts of face                          |
| D03.4   | Melanoma in situ of scalp and neck                               |
| D03.51  | Melanoma in situ of anal skin                                    |
| D03.52  | Melanoma in situ of breast (skin) (soft tissue                   |
| D03.59  | Melanoma in situ of other part of trunk                          |
| D03.60  | Melanoma in situ of unspecified upper limb, including shoulder   |
| D03.61  | Melanoma in situ of right upper limb, including shoulder         |
| D03.62  | Melanoma in situ of left upper limb, including shoulder          |
| D03.70  | Melanoma in situ of unspecified lower limb, including hip        |
| D03.71  | Melanoma in situ of right lower limb, including hip              |
| D03.72  | Melanoma in situ of left lower limb, including hip               |
| D03.8   | Melanoma in situ of other sites                                  |
| D03.9   | Melanoma in situ, unspecified                                    |

## References

Specialty-matched clinical peer review.

Hyperthermia for Treatment of Cancer. National Coverage Determination (NCD) 110.1. Accessed January 15, 2020. <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?TAId=5&MEDCACId=9&CALId=185&MCDId=13&NCAId=1&NcaName=Actinic+Keratosis&NCDId=66&ncdver=1&SearchType=Advanced&CoverageSelection=National&NCSelection=NCA%7CCAL%7CNCD%7CMEDCAC%7CTA%7CMD&kq=true&bc=IAAABAAAAAAAA%3D%3D&>. Accessed January 19, 2022.

National Comprehensive Cancer Network (NCCN) Guidelines®. Version 1.2020 – January 15, 2019. Breast Cancer. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Version 1.2020. 2020 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of the NCCN®. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org

Overgaard J, Gonzalez D, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995 Mar 4; 345(8949):540-543

Sonotherm® 1000 Ultrasound Therapy System.

Valdagni R, Amichetti M. Report of long-term follow up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients. Int. J. Radiat. Oncol. Biol. Phys. 1994 Jan 1; 28(1):163–169. 11.

Vernon CC, Hand JW, Field SB et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys. 1996 Jul 1; 35(4):731-744.